News & Blog

Author Archives: Tom Halkin

Encouraging Results from Novocure Clinical Trial

Novocure, a company that creates medical devices to treat cancer, announced this weekend that their Novo-TTF-100A system (now being called Optune), in combination with temozolomide (also know as Temodar or TMZ), demonstrated improved survival in newly diagnosed glioblastoma multiforme (GBM) patients in a clinical trial, compared with temozolomide alone. The announcement was made at the […]

Can this treatment help me live a longer and better life?

Why was I asked to sit on a panel with two top officials from the U.S. Food and Drug Administration (FDA), two leading neuro-oncologists, an associate professor of neuropsychiatry, and an executive from the biopharmaceutical company, Genentech? Because, as a five-year brain tumor survivor and volunteer advocate with the National Brain Tumor Society, I want […]

Creating Meaningful Change, With a Little Help From our Friends

There are only four FDA-approved therapies to treat brain tumors. And in the last 17 years there have been approximately 75 potential new drugs that have failed during the clinical trial process to prove they are safe and effective for patients, while only three that have won FDA approval[1]. That is a 25:1 failure ratio. […]

Share